Ken Griffin Kezar Life Sciences, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.53 - $0.77 $5,618 - $8,162	10,600 Added 331.25%	13,800 $10,000
Q2 2024 Aug 14, 2024	BUY	$0.6 - $0.92 $360 - $552	600 Added 23.08%	3,200 $1,000
Q1 2024 May 15, 2024	SELL	$0.8 - $1.05 $78,240 - $102,690	-97,800 Reduced 97.41%	2,600 $2,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.15 $1,152 - $1,839	1,600 Added 1.62%	100,400 $95,000
Q3 2023 Nov 14, 2023	SELL	$1.08 - $2.54 $1,296 - $3,048	-1,200 Reduced 1.2%	98,800 $117,000
Q2 2023 Aug 14, 2023	BUY	$2.31 - $3.06 $231 - $306	100 Added 0.1%	100,000 $245,000
Q1 2023 May 15, 2023	BUY	$3.13 - $7.31 $15,337 - $35,819	4,900 Added 5.16%	99,900 $312,000
Q4 2022 Feb 14, 2023	SELL	$6.39 - $8.8 $316,305 - $435,600	-49,500 Reduced 34.26%	95,000 $668,000
Q3 2022 Nov 14, 2022	SELL	$7.99 - $10.75 $661,572 - $890,100	-82,800 Reduced 36.43%	144,500 $1.24 Million

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $449M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.